You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 10, 2025

Drug Price Trends for MESALAMINE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for MESALAMINE

Average Pharmacy Cost for MESALAMINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
MESALAMINE 1,000 MG SUPP 00472-1915-30 1.45171 EACH 2025-01-22
MESALAMINE 1,000 MG SUPP 16714-0245-30 1.45171 EACH 2025-01-22
MESALAMINE 1,000 MG SUPP 31722-0005-30 1.45171 EACH 2025-01-22
MESALAMINE 1,000 MG SUPP 16714-0245-01 1.45171 EACH 2025-01-22
MESALAMINE ER 500 MG CAPSULE 63304-0089-13 3.63689 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for MESALAMINE

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
MESALAMINE 1000MG SUPP,RTL Golden State Medical Supply, Inc. 70710-1302-07 5X6 149.18 2023-06-15 - 2028-06-14 FSS
MESALAMINE 400MG CAP,EC AvKare, LLC 00093-5907-86 180 509.58 2.83100 EACH 2023-08-07 - 2028-06-14 FSS
MESALAMINE 1000MG SUPP,RTL AvKare, LLC 00472-1915-30 30 30.29 1.00967 EACH 2023-06-15 - 2028-06-14 FSS
MESALAMINE 1200MG TAB,EC AvKare, LLC 00591-2245-22 120 198.39 1.65325 EACH 2023-06-15 - 2028-06-14 FSS
MESALAMINE 4GM/60ML SUSP,RTL ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc. 62559-0420-07 7X60ML 20.64 2023-01-01 - 2027-07-14 Big4
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Mesalamine Market Analysis and Price Projections

Overview of Mesalamine

Mesalamine, also known as Mesalazine, is a prescription drug containing 5-aminosalicylic acid, primarily used to treat ulcerative colitis (UC) and other inflammatory bowel diseases. It has been a first-line agent for the treatment of active UC since the 1940s[4].

Market Size and Growth

The global mesalamine market has been experiencing steady growth. As of 2021, the market size was valued at approximately $169.5 million. It is forecast to reach $212.6 million by 2030, with a compound annual growth rate (CAGR) of 3.8% during the forecast period from 2022 to 2030[1].

Another projection indicates that the market size could reach $211.6 million by 2027, growing at a CAGR of 3.4% from 2020 to 2027[4].

Regional Analysis

  • North America: This region is expected to hold the largest share of the mesalamine market due to growing awareness about the benefits of the drug, the presence of prominent pharmaceutical firms, and government funding and incentives for healthcare development[1][4].
  • Europe: Europe also contributes significantly to the market, driven by the increasing prevalence of bowel diseases in the region[4].
  • Other Regions: The Asia Pacific, South America, and the Middle East and Africa regions are also expected to grow, driven by increasing healthcare expenditure and investment in R&D[4].

Market Drivers

  • Increasing Awareness and Prevalence of IBD: The rising global occurrence of inflammatory bowel diseases such as ulcerative colitis is a major driver for the demand of mesalamine[3][4].
  • Advancements in Drug Formulations: Technological advancements in drug formulations, such as extended-release and combination therapies, are enhancing the efficacy and patient compliance of mesalamine[3].
  • Expansion of Healthcare Infrastructure: Global expansion of healthcare infrastructure and increasing investment in R&D are providing ample growth opportunities for the mesalamine market[1][3].
  • COVID-19 Impact: Despite initial disruptions, the COVID-19 pandemic has positively impacted the market by increasing healthcare expenditure and focus on pharmaceutical research and development[1].

Market Restraints

  • Adverse Side Effects: Mesalamine treatments can cause side effects such as nausea, vomiting, fever, headache, stomach and abdominal pain, and rash, which can limit its adoption[4].
  • Alternative Therapies: The availability of alternative treatments poses a competitive threat to the mesalamine market[3].
  • Regulatory Requirements: Stringent regulatory requirements can also hinder the market growth[3].

Market Opportunities

  • Generic Versions and Cost-Effectiveness: Patent expirations offer opportunities for generic versions of mesalamine, making it more accessible and cost-effective[3].
  • Telemedicine and Digital Health: Leveraging telemedicine and digital health platforms can facilitate easier access and adherence to mesalamine treatments[3].
  • Emerging Markets: Growing healthcare expenditure in emerging markets presents significant opportunities for market expansion[3].

Price Projections and Cost Analysis

The cost of mesalamine varies based on the form and dosage of the medication.

  • Oral Delayed Release Tablet:
    • 1.2 g oral delayed release tablet: around $89 for a supply of 30 tablets[2].
    • 800 mg oral delayed release tablet: from $427.70 for 30 tablets[2].
  • Oral Capsule, Extended Release:
    • 0.375 g: from $79.78 for 20 capsules[2].
    • 500 mg: from $678.44 for 120 capsules[2].
  • Rectal Enema:
    • 1000 mg rectal suppository: from $368.51 for 30 suppositories[2].

Competitive Landscape

The global mesalamine market is competitive, with key players including:

  • Mylan N.V.
  • Teva Pharmaceuticals
  • Ferring B.V.
  • Allergan
  • Bausch Health Companies Incorporated (Salix Pharmaceutical)[4].

Future Trends

  • New Product Releases: New product releases, especially in extended-release and combination therapies, are expected to drive market growth[4].
  • Patient Support Programs: Growing patient support programs are providing opportunities for market expansion[4].
  • Regulatory Pathways: Assessing regulatory pathways for mesalamine approval in countries with growing healthcare infrastructure is crucial for future growth[3].

Key Takeaways

  • The global mesalamine market is projected to grow at a CAGR of 3.4% to 3.8% from 2022 to 2030.
  • North America and Europe are the leading regions due to high awareness and prevalence of IBD.
  • Advancements in drug formulations and expanding healthcare infrastructure are key drivers.
  • Adverse side effects and alternative therapies are significant restraints.
  • Generic versions and telemedicine platforms offer future growth opportunities.

FAQs

1. What is mesalamine used for? Mesalamine is primarily used to treat ulcerative colitis (UC) and other inflammatory bowel diseases.

2. What is the forecasted growth rate of the mesalamine market? The mesalamine market is forecasted to grow at a CAGR of 3.4% to 3.8% from 2022 to 2030.

3. Which region holds the largest share of the mesalamine market? North America holds the largest share of the mesalamine market due to growing awareness and the presence of prominent pharmaceutical firms.

4. What are the main drivers of the mesalamine market? The main drivers include increasing awareness and prevalence of IBD, advancements in drug formulations, and the expansion of healthcare infrastructure.

5. What are the potential restraints to the mesalamine market? Adverse side effects, alternative therapies, and stringent regulatory requirements are significant restraints to the mesalamine market.

Sources

  1. Report Ocean: Mesalamine Market Size, Share & Trends Analysis.
  2. Drugs.com: Mesalamine Prices, Coupons, Copay Cards & Patient Assistance.
  3. 360iResearch: Mesalamine Market Size & Share 2025-2030.
  4. MarketStatsville: Mesalamine Market Share Size Value Analysis and Forecast 2027.
  5. NewsChannel Nebraska: Mesalamine Market Growth Insights 2024: Competitive Strategies.

More… ↓

⤷  Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.